How does your compound reduce neurodegenerative processes or ageing?
Disrupted mitochondrial function contributes to premature ageing of the central nervous system. The pathogenesis of many major neurological conditions – Alzheimer’s, Parkinson’s and Huntington’s disease, ischaemic stroke, neuropsychiatric disorders – has also been linked to mitochondrial dysfunction.
To investigate the potential effects of compounds developed to reduce and/or prevent ageing and neurodegenerative process, the assays run on our MitoXpert® platform assess mitochondrial function in neuronal cells (neuroblastoma).
![](https://www.mitologics.com/wp-content/uploads/2023/06/Efficacy-CNS-1024x574.webp)
Sustained mitochondrial damage results in energy metabolism dysfunction, decreased ATP production, increased reactive oxygen species (ROS) burden, and reduced calcium buffering. All of these effects lead to neuron loss, a contributor to both acute and chronic degenerative neurological disorders.
With MitoXpert®, you can investigate mitochondrial functionality on pathological CNS cellular models, focusing on:
These assays can be performed in basal or pathological conditions, by provoking metabolic or oxidative stress, or implementing an ischaemia/reperfusion model (hypoxia and glucose deprivation).
Direct effect of compounds can also be evaluated on isolated mitochondria from rodent brain, in compliance with the 3R principle.